Indian Dermatology Online Journal

CONCISE COMMUNICATION
Year
: 2021  |  Volume : 12  |  Issue : 2  |  Page : 330--334

Amyloidosis cutis dyschromica, A rare subtype of primary cutaneous amyloidosis: Case report and literature review


Jagdish Sakhiya1, Dhruv Sakhiya2, Mehul Patel1, Feral Daruwala1,  
1 Department of Dermatology, Sakhiya Skin Clinic PVT LTD, Surat, Gujarat, India
2 MBBS Student. B.J. Medical College, New Civil Hospital Asarwa, Ahmedabad, Gujarat, India

Correspondence Address:
Jagdish Sakhiya
Sakhiya Skin Clinic PVT LTD. 2ndFloor, Ayush Docter House, Station-Lal Darwaja Road, Surat - 395 003, Gujarat
India




How to cite this article:
Sakhiya J, Sakhiya D, Patel M, Daruwala F. Amyloidosis cutis dyschromica, A rare subtype of primary cutaneous amyloidosis: Case report and literature review.Indian Dermatol Online J 2021;12:330-334


How to cite this URL:
Sakhiya J, Sakhiya D, Patel M, Daruwala F. Amyloidosis cutis dyschromica, A rare subtype of primary cutaneous amyloidosis: Case report and literature review. Indian Dermatol Online J [serial online] 2021 [cited 2022 Jan 20 ];12:330-334
Available from: https://www.idoj.in/text.asp?2021/12/2/330/310627


Full Text



Sir,

In 1970, Morishima et al. introduced amyloidosis cutis dyschromica (ACD), a rare variant of primary cutaneous amyloidosis (PCA). ACD is characterized by the presence of hyperpigmented and hypopigmented or depigmented macules of varying sizes in generalized fashion associated with no or little pruritus, prepubertal onset, and focal amyloid deposition in the papillary dermis.[1],[2] We present a case of ACD developed in a 9 yearold Indian girl, who was treated with combination of acitretin, the excimer light and fractional CO2 laser.

A 9-year-old Indian girl born to parents of first degree consanguineous marriage presented with generalized, asymptomatic hyperpigmentation since 3 months of age and, three months later mottled hypopigmented macules developed involving the face, abdomen, back, and both upper and lower extremities [Figure 1]a,[Figure 1]b,[Figure 1]c,[Figure 1]d. The hypopigmented macular lesions initially appeared on her face and, then gradually extended to involve the abdomen, back, and both upper and lower extremities within a month. There was no associated pruritus, erythema, telangiectasia, atrophy or blisters. There was no preceeding epiosdes of photosensitivity, inflammatory cutaneous conditions or systemic illness. Her mental developmental milestones were normal and family history was non-contributory. A general physical examination, as well as systemic examination, was unremarkable and routine laboratory parameters were within normal limits. Cutaneous examination revealed diffuse hyper pigmentation with mottled spotty, well-defined and hypo pigmented macules ranging from pinpoint to 3mm diameters in size and some of the hypo pigmented macules coalesced to form macule of 1 × 1 cm. Hair, teeth, nails and oral mucosa were normal. Ophthalmology and ENT assessments were non-contributory. For histopathological examination, punch biopsy samples were taken from both hyper- and hypopigmented macular lesions, from the sun-protected site, i.e., lower back, stained with hematoxylin-eosin stain and observed under light microscopy. The pathological section from both lesions revealed a few widened papillae which had small globular pink amorphous deposits of amyloid in association with occasional melanophages. The amyloid deposits were present at the interface and associated with moderately hyperplastic rete ridges. The epidermis showed moderate compact and lamellated orthohyperkeratosis. Occasional dyskeratotic cells were seen within the upper epidermis [Figure 2]. Later on, the presence of these amyloid deposits was confirmed by congo red staining which had been shown apple-green birefringence with polarised light [Figure 3]. Based on these typical clinical features, histopathological findings, and positive Congo red staining; the diagnosis of ACD was confirmed. After diagnosis, the patient was started on combined therapy of oral acitretin (25 mg oral daily) with 308nm excimer light at a dose of 200mJ/cm2, monthly and, fractional CO2 laser (10,600nm) 1 × 1 spot size along with 4 mJ power once per month. And in the form of repigmentation, partial improvement was observed within the mottled hypopigmented macules of the face [Figure 4]. Acitretin drug therapy was prescribed for 6 months and, until now, the sixth session of the laser has been provided. Currently, the patient was on a similar treatment at the time of article writing.{Figure 1}{Figure 2}{Figure 3}{Figure 4}

Cutaneous amyloidosis has been classified into three major types: PCA, secondary cutaneous amyloidosis, and systemic cutaneous amyloidosis. Of these, PCA is classified into three subtypes: Lichen or papular, macular, and nodular or tumefactive. Lichen amyloidosis is the most common type and clinically characterized by an intensely pruritic eruption. Multiple discrete hyperkeratotic papules may coalesce into plaques and are often located on the extensor surfaces of the legs. Macular amyloidosis presents as brownish macules and has been often distributed in a rippled pattern on the upper aspect of the back. Nodular amyloidosis is a rare form of PCA and presents as a solitary or multiple erythematous to brownish waxy nodules on the legs or the trunk. Rare variants of PCA include familial poikiloderma-like cutaneous amyloidosis, bullous, vitiliginous, anosacral, and ACD.[1],[2] ACD is mostly reported from the Southeast Asian countries.[3] To date, from the Indian subcontinent, only seven cases of ACD have been reported. The clinical, histopathological and treatment profile of these published cases of ACD has been compiled in [Table 1].[4],[5],[6],[7],[8],[9],[10]{Table 1}

ACD must be differentiated from other causes of dyschromia including dyschromatosis universalis hereditaria, xeroderma pigmentosum and poikiloderma-like amyloidosis. The former two conditions do not exhibit amyloid deposits in the skin. The latter shows a similar clinical cutaneous picture as ACD but with additional features such as poikilodermic lesions, lichenoid papules, blisters, photosensitivity, short stature and palmoplantar keratoderma.[1] In the presented case, amyloid deposition could be seen in the histopathology report and absence of the above mentioned additional feature confirmed the diagnosis of ACD.

The occurrence of familial cases and disease onset before puberty suggests a genetic aetiology of ACD. The genetic basis of ACD is not known. In particular, biallelic mutations in GPNMB, encoding glycoprotein (transmembrane) nonmetastatic melanoma protein B, have been mainly assumed to be involved in the pathogenesis of ACD.[11] It has recommended that genetic factors may lead to the disruption of DNA repair in keratinocytes. Moriwaki et al., Vijaikumar, and Thappa observed slow DNA repair in keratinocytes due to ultraviolet C damage and reduced repair following ultraviolet B damage.[2],[4] However, the cutaneous findings in the presented case revealed that hyperpigmented macules and mottled hypopigmented macules distributed over the entire skin surface, and the face, back, and both upper and lower extremities often had a similar presentation as the abdomen which was the non-sun-exposed skin area. These findings argue against a primary role of photosensitivity in the presented case. Onset before puberty may be a crucial contributory factor in the pathogenesis of ACD in this case.

Histopathological examination showed amyloid deposits in the papillary dermis. Amyloid stains positively for crystal violet and Congo red. In rare instances, amyloid is not detected with the former stains, immunochemistry for anti-cytokeratin antibodies should be obtained if suspicion remains. Here, in this case, congo red stain was used for a definite diagnosis of ACD.[12]

Various treatment modalities have been described for the treatment of ACD with varying success rates. Protection from sun exposure and the use of broad-spectrum sunscreen should be advised for all the patients. Variable results have been obtained with topical corticosteroids, keratolytic, dimethyl sulfoxide, UV-B and psoralen–UV-A phototherapy, dermabrasion, capsaicin, and CO2 laser. However, success is limited. Prudent management is of great value in this condition. As per the literature review, systemic acitretin treatment seems to have the most promising results.[13] It is a synthetic retinoid, is the pharmacologically active metabolite of etretinate, may act by repairing the keratinization defect that causes the degeneration of keratin fibrils to amyloid. The excimer light is a quite effective modality for treating hypopigmentation, on this ground; we thought to combine it with acitretin. Fractional CO2 laser passes light down to the deeper layers of the skin, causing controlled damage to the cells and, triggering the skin's natural healing process. This process allows the cells to be trained to grow back stronger, firmer and faster, therefore the skin becomes smoother, tighter and more even in tone. Regarding this mechanism, fractional CO2 laser was used for even distribution of pigmentation in surrounding areas. The healing time for the laser is 2-3 days. In particular, the higher frequency of excimer light and high power of fractional CO2 laser may cause post-inflammatory hyper-pigmentation in dark and dry skin, as a cosmetic point of view, this is a grave matter. As expected, the combination of acitretin with the excimer light and fractional CO2 laser with specific settings worked well for this condition and resulted in improved cosmesis.

Histopathological evaluation with specific stain congo red is the best clue for the diagnosis of ACD. The partial improvement over facial skin was noted with combined treatment of acitretin with excimer light and fractional CO2 laser.

Consent for publication

Written informed consent was obtained from the patient's legal guardian(s) for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Acknowledgement

We would like to thank all the authors for the contribution to this work.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1Morishima T. A clinical variety of localized cutaneous amyloidosis characterized by dyschromia (amyloidosis cutis dyschromica). Jpn J Dermatol B 1970;3:43-52.
2Moriwaki S, Nishigori C, Horiguchi Y, Imamura S, Toda K, Takebe H. Amyloidosis cutis dyschromica. DNA repair reduction in the cellular response to UV light. Arch Dermatol 1992;128:966-70.
3Tan T. Epidemiology of primary cutaneous amyloidoses in Southeast Asia. Clin Dermatol 1990;8:20-4.
4Vijaikumar M, Thappa DM. Amyloidosis cutis dyschromica in two siblings. Clin Exp Dermatol 2001;26(8):674–6.
5Choonhakarn C, Wittayachanyapong S. Familial amyloidosis cutis dyschromica: Six cases from three families. J Dermatol 2002;29:439–42.
6Kurian SS, Rai R, Mahukar ST. Amyloidosis cutis dyschromica. Indian Dermatol Online J 2013;4:344–6.
7Garg T, Chander R, Jabeen M, Barara M, Mittal M, Jain M. Amyloidosis cutis dyschromica: A rare pigmentary disorder. J Cutan Pathol 2011;38:823–826.
8Verma S, Joshi R. Amyloidosis cutis dyschromica: A rare reticulate pigmentary dermatosis. Indian J Dermatol 2015;60:385-7.
9Tiwary AK, Mishra DK, Chaudhary SS. Amyloidosis cutis dyschromica: A rare dyschromic subtype of primary cutaneous amyloidosis. Pigment Int 2016; 3:33.
10Verma K, Sharma RK, Gulati A, Gupta M. Amyloidosis cutis dyschromica: A rare dyschromic pigmentary disorder. Indian J Dermatopathol Diagn Dermatol 2019;6:45-7.
11Yang CF, Lin SP, Chiang CP, Wu YH, H'ng WS, Chang CP. Loss of GPNMB Causes Autosomal-Recessive Amyloidosis Cutis Dyschromica in Humans. Am J Hum Genet 2011;102:219–232.
12Huang WH, Wu CY, Yu CP, Chiang CP. Amyloidosis cutis dyschromica: Four cases from two families. Int J Dermatol 2009;48(5):518-21.
13Mahon C, Oliver F, Purvis D, Agnew K. Amyloidosis cutis dyschromica in two siblings and review of the epidemiology, clinical features and management in 48 cases. Australas J Dermatol. 2016;57(4):307-311.